Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Pathology

What oncology patients say about pathology reports

March 2025—A study of oncology patients at the Medical College of Wisconsin sheds light on how they perceive the content and timing of pathology report review. The study findings were gathered through in-person and telehealth interviews with patients with breast, endocrine, gastrointestinal, genitourinary, and thoracic malignancies. Medical student Amber Y. Bo, MD, in 2022 and 2023 conducted 230 interviews with patients who had a prior opportunity to review their reports in the patient portal.

Department takes digital pathology to new level

January 2025—Pathology informatics leaders at the University of Michigan are moving in steps to a fully digital practice as they put in place an innovative workflow for primary diagnosis. Fresh off their August launch of the new workflow program within their remodeled histology lab, informatics directors in the pathology department say Michigan Medicine is the first in the U.S. to have radiology and pathology operating in the same shared picture archiving and communication system, or PACS, and to implement the well-established DICOM standard for pathology workflow.

Should grade group 1 prostate cancer be renamed?

January 2025—Whether grade group 1 prostate cancer should be renamed to “noncancer” was the center of debate on a CAP podcast last fall led by Gladell P. Paner, MD, in discussion with Ming Zhou, MD, PhD, and Rajal B. Shah, MD. Dr. Paner is professor of pathology and surgery, University of Chicago Pritzker School of Medicine, and director of the genitourinary pathology service and of the reproductive endocrinology and infertility laboratory, UChicago Medicine.

Digital pathology at 10% adoption and in lab plans

December 2024—Digital pathology in 2024—what’s the sentiment, the pace, the holdup, the worry? Five people spoke online with CAP TODAY publisher Bob McGonnagle on Oct. 9 about the state of play as the end of the year neared.

Payment policy changes reduce ’25 cuts to pathologists

December 2024—Payment policies that the CAP championed to protect the value of pathology services have been captured in the 2025 Medicare physician fee schedule published on Nov. 1. The Centers for Medicare and Medicaid Services included in the 2025 fee schedule updated relative value units for three apheresis services and increased nonphysician cost components for key pathology and laboratory labor types. In a separate hospital payment regulation for 2025, the CMS also declined to move forward with surgical pathology tissue exam payment decreases to which the CAP objected.

Surveying cancer protocol use far and wide

November 2024—Members of the CAP Foundation Global Pathology Committee and the CAP Cancer Committee collaborated to develop a three-part webinar series on how to use the CAP cancer protocols. The webinars were directed to international pathologists, particularly those in low- and middle-income countries.

New Enhertu use, new HER2 complexities

September 2024—Every profession has its own news cycle. In pathology, the story arc is often a lengthy one, stretching from clinical triumph to Now what? Such is the case with expanded use of trastuzumab deruxtecan, which was granted accelerated FDA approval in late April for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received prior systemic treatment and have no alternative treatment options. Three multicenter trials evaluated the efficacy of the drug: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. PanTumor02 looked at seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other solid cancers (excluding breast, colorectal, gastric, and non-small cell lung cancers). The results of these trials often were striking (median duration of response for PanTumor02 was 19.4 months, for example), and physicians are now looking closely at this tumor-agnostic (also referred to as tissue-agnostic) indication.

Intraop neuropathology consultation: tips and cases

September 2024—Leomar Ballester, MD, PhD, of the University of Texas MD Anderson Cancer Center has simple advice for those called to provide an intraoperative neuropathologic consultation: review the imaging and know the entities.

Eyes on LDT inventory and cyberattack readiness

September 2024—The ADLM meeting in Chicago had just wrapped up when Compass Group members met online Aug. 6 with CAP TODAY publisher Bob McGonnagle. Stan Schofield, Compass Group VP and managing principal, noted Allina Health had announced in late June its definitive agreement with Quest Diagnostics for select assets of Allina’s laboratory services business, and Schofield reported plenty of M&A talk at the ADLM meeting. The group’s August discussion began there and moved to laboratory-developed tests and cybersecurity.

MARKETPLACE

TRENDING